Ryman Healthcare (RYM) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
12 Jan, 2026Executive summary
Net profit after tax fell 50% to $94.4 million for the period, with negative cash flow from existing operations and a board and executive renewal, including a new CEO and functional structure.
Significant business improvement initiatives delivered $18 million in annualized savings, with further cost reductions targeted and a new pricing structure launched.
The company operates 49 villages, over 9,500 retirement units, and 4,600 aged care beds, with a growing presence in Victoria, Australia.
Major accounting policy changes and restatements were implemented to enhance transparency and comparability, including DMF discounting removal and reclassification of development land.
No interim dividend declared for the period; dividend policy to be reviewed in FY26.
Financial highlights
Net profit after tax was $94.4 million, down 49.5% from $187.1 million year-over-year, with revenue rising 10% to $366.3 million and operating expenses up 18% to $351.7 million.
Net profit before tax and fair value movements was a loss of NZD 79.8 million, down NZD 17.8 million year-over-year.
Cash flow from existing operations was negative $7.8 million, a $24.8 million decline year-over-year; free cash flow improved to negative $52.5 million.
Cash flow from development improved to negative $44.7 million, a $132 million improvement year-over-year.
Gross resale margin compressed to 26.6%, down three points year-over-year due to flat pricing.
Outlook and guidance
Free cash flow for FY25 now expected to be negative $50–100 million, revised from previous positive guidance, as settlements are deferred into FY26.
Capital expenditure guidance reduced to $625–675 million, down from $700–820 million.
Delivery of retirement units and aged care beds expected at the top end of 850–950 range.
Further business improvement savings targeted by end of FY26.
Deferred management fee structure changed to a choice of 30% or 25% with a higher entry price, expected to increase future taxable cash flows.
Latest events from Ryman Healthcare
- Targeting NZD 150m cash flow uplift and NZD 500m cash release by FY 2029, with resumed dividends.RYM
Investor Day 20264 Feb 2026 - Strategic reset, board overhaul, and $1B equity raise drive focus on value recovery.RYM
AGM 20253 Feb 2026 - Cash flow up, profit down, dividends suspended, new villages opened, sector funding tight.RYM
AGM 20242 Feb 2026 - First positive free cash flow in a decade, with revenue up 13% but a net loss of $45.2m.RYM
H1 202627 Nov 2025 - Record build, improved cash flow, and cost savings set up for disciplined FY26 growth.RYM
H2 202520 Nov 2025